Brief: Windtree Completes Enrollment In Its Phase 2 Study Of Lucinactant

Windtree Therapeutics

01/02/2022 12:31

Feb 1 (Reuters) - Windtree Therapeutics Inc  WINT.O :
    * WINDTREE COMPLETES ENROLLMENT IN ITS PHASE 2 STUDY OF
LUCINACTANT (KL4 SURFACTANT) FOR COVID-19 ASSOCIATED LUNG INJURY
AND ACUTE RESPIRATORY DISTRESS SYNDROME
    * WINDTREE THERAPEUTICS INC - DATA FROM PHASE 2 STUDY OF
LUCINACTANT (KL4 SURFACTANT) ANTICIPATED IN Q1 OF 2022

Source text for Eikon:  ID:nGNXbBVD9C 
Further company coverage:  WINT.O 

 ((Reuters.Briefs@thomsonreuters.com;))